Germany plans to extend pharma price freeze, rebates
This article was originally published in Scrip
Despite the large and growing surplus in the health insurance accounts, the incoming German government is planning to extend the freeze on pharmaceutical prices beyond the end of this year. It also intends to continue with mandatory rebate contracts on drug sales to the statutory health insurance, albeit at a lower rate.
You may also be interested in...
As part of its efforts to preserve patient access to medicines amid the COVID-19 pandemic, Russia is planning to cap drug prices if increases of more than 30% are detected. It will also allow online sales of non-prescription drugs and may also tighten the rules on fake and substandard products.
France is exploring the use of hydroxychloroquine and lopinavir/ritonavir in COVID-19, but only in hospitalized patients and in clinical trials, and has banned all exports of the products to avoid possible shortages.
Efforts are under way in the UK on many fronts to develop new treatments and vaccines for coronavirus infection, including researching new uses of existing products and clinical trials of new vaccines.